Lerman GI

Language: Spanish
References: 15
Page: 62-65
PDF size: 65.38 Kb.

Text Extraction

No abstract

REFERENCES

1. Gómez-Pérez FJ, Rull JA. Insulin therapy: current alternatives. Arch Med Res 2005; 36: 258-72.

2. Bolli GB, DiMarchi RD, Park GD, Koivisto VA. Insulin analogues and their potential in the management of diabetes mellitus. Diabetología 1999; 42: 1151-1167.

3. Yki JH, Kauppila M, Kujensuu E et al. Comparison of insulin regimens in patients with non-insulin dependent diabetes mellitus. N Engl J Med 1992; 327: 1426-1433.

4. Riddle M, Rosenstock J, Gerich J. Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.

5. Hermansen K, Davies M, Deresinski T, Martínez RG. A 26 week, randomized, parallel, treat to target trial comparing insulin detemir with NPH insulin as add on therapy to oral glucose lowering drugs in insulin naïve people with type 2 diabetes. Diabetes Care 2006; 29: 1269-1274.

6. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.

7. Quayyum R, Bolen Sh, Maruthur N et al. Systematic review: Comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. Ann Intern Med 2008; 149: 1-11.

8. Gale EA, for the U.K. Trial Group. A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med 2000; 17: 209-214.

9. Hermansen K, Fontaine P, Kukolja KK, PeterkovaV, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH and regular human insulin) in basal–bolus therapy for patients with Type 1 diabetes. Diabetología 2004; 47: 622-629.

10. White NH, Neil H, Chase P, Arslanian S, Tamborlane WV. Comparison of glycemic variability associated with insulin glargine and intermediate acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes. Diabetes Care 2009; 32: 387-393.

11. Anderson JH, Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analog treatment. Diabetes 1997; 46: 265-270.

12. Pieber TR, Treichel HC, Hompescht B, Philotheu A, Mordhorst L, Gall MA, Robertson LI. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diab Med 2007; 24: 635-42.

13. Rattner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000; 23: 639-643.

14. Porcellati F, Rossetti P, Pampanelli S, Fanelli CG, Torlone E, Scionti L, Periello G, Bolli GB. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med 2004; 21: 1213-1220.

15. Smith U, Gale EAM. Does diabetes therapy influence the risk of cancer? Diabetología DOI 10.1007/s00125-009-1441-5.